Skip Navigation



Journal of the National Cancer Institute Advance Access published online on November 5, 2009
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djp402
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Oakman, C.
Right arrow Articles by Di Leo, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oakman, C.
Right arrow Articles by Di Leo, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved.

CORRESPONDENCE

Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy

Catherine Oakman, Erica Moretti, Christos Sotiriou, Giuseppe Viale, Angelo Di Leo

Affiliations of authors: Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy (CO, EM, ADL); Translational Research Unit, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium (CS); Department of Pathology, University of Milan, European Institute of Oncology, Milan, Italy (GV)

Correspondence to: Angelo Di Leo, MD, PhD, "Sandro Pitigliani" Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy (e-mail: adileo@usl4.toscana.it).

The first 10% of the full text of this article appears below.

O'Malley et al. (1) advocated a role for TOP2A alteration and HER2 amplification status in prediction of incremental benefit from anthracycline-based adjuvant chemotherapy in breast cancer. We believe that, with current evidence, it is inappropriate to conclude that anthracycline benefit may be predicted by HER2 and/or TOP2A status.

. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?